Research Topics
Genomes and Genes | Helen McShaneSummaryAffiliation: University of Oxford Country: UK Publications
| Collaborators
|
Detail Information
Publications
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosisSarah C Gilbert
Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
Vaccine 24:4554-61. 2006..In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials...- Tuberculosis vaccines: current status and future prospectsHelen Fletcher
University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
Expert Opin Emerg Drugs 11:207-15. 2006..Research efforts that focus on reducing the cost and risk of conducting clinical trials will be of direct benefit to tuberculosis vaccine development... - Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine stainingSteven G Smith
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
BMC Immunol 11:35. 2010..The aim of this study was to identify which cytokines and lymphocyte populations characterise the peripheral blood cellular immune response following BCG vaccination... - Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosisH McShane
Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Infect Immun 69:681-6. 2001.... - Prime-boost immunisation strategies for tuberculosisHelen McShane
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
Microbes Infect 7:962-7. 2005..Using BCG as the priming immunisation in such a heterologous prime-boost strategy is a practical solution, which allows the beneficial effects of BCG in children to be maintained... - Co-infection with HIV and TB: double troubleHelen McShane
Harrison Clinic, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
Int J STD AIDS 16:95-100; quiz 101. 2005..Indications for chemoprophylaxis and vaccination against TB are reviewed... - Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humansHelen McShane
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
Nat Med 10:1240-4. 2004..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas... - Developing an improved vaccine against tuberculosisHelen McShane
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
Expert Rev Vaccines 3:299-306. 2004..The issues surrounding the progression of the most promising candidates into Phase I clinical trials are also discussed... - Vaccine strategies against tuberculosisHelen McShane
The Jenner Institute, University of Oxford, Oxford, UK
Swiss Med Wkly 139:156-60. 2009..In addition, the cellular immune response induced is highly polyfunctional. The protective efficacy of MVA85A will be evaluated in a Phase IIb trial commencing in early 2009 in South African infants... - Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85AHelen McShane
Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Infect Immun 70:1623-6. 2002.... - Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trialsHelen McShane
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
Tuberculosis (Edinb) 85:47-52. 2005..MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed... - Need for more TB vaccine field sitesHelen McShane
The Jenner Institute, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ
Indian J Exp Biol 47:445-6. 2009..There is currently inadequate capacity within high-burden TB countries to conduct these essential trials. We need to invest now to expand current capacity if we are to reduce the time taken to develop new vaccines... - Prime-boost immunization strategies for infectious diseasesHelen McShane
Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, UK
Curr Opin Mol Ther 4:23-7. 2002..Prime-boost immunization strategies involve using two different vaccines, each encoding the same antigen, some weeks apart. Such strategies have been shown to enhance cellular immunity in several different animal and disease models... - Tuberculosis vaccines: beyond bacille Calmette-GuerinHelen McShane
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
Philos Trans R Soc Lond B Biol Sci 366:2782-9. 2011..This article reviews the leading candidate vaccines in development and considers the current challenges in the field with regard to efficacy testing... - Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in miceEmily K Forbes
The Jenner Institute, University of Oxford, Headington, Oxford, United Kingdom
J Immunol 181:4955-64. 2008..Successful immunization regimes appear to induce Ag-specific cells with abundant intracellular cytokine staining... - Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85AKathryn T Whelan
Jenner Institute, University of Oxford, Churchill Hospital, Oxford, United Kingdom
PLoS ONE 4:e5934. 2009.... - Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosisElma Z Tchilian
The Jenner Institute, Oxford University, ORCRB, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
Infect Immun 77:622-31. 2009..This emphasizes the need for new biomarkers for the evaluation of TB vaccine efficacy... - Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trialsAnsar A Pathan
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom
PLoS ONE 2:e1052. 2007.... - A comparison of IFNgamma detection methods used in tuberculosis vaccine trialsNatalie E R Beveridge
Jenner Institute, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK
Tuberculosis (Edinb) 88:631-40. 2008..Future tuberculosis vaccine trials and immunology studies should ideally include a combination of ex vivo and cultured assays to ensure a thorough and multifaceted evaluation of the immune response is achieved... - Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populationsNatalie E R Beveridge
Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Eur J Immunol 37:3089-100. 2007..Overall, these data strongly support the use of MVA85A in humans as a boosting agent to expand polyfunctional M.tb-specific CD4(+) T cells capable of significant secondary responses... - Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeedingEung Jun Im
Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford OX3 9DS, United Kingdom
J Virol 81:9408-18. 2007.... - Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus AnkaraNilu P Goonetilleke
Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
J Immunol 171:1602-9. 2003..These findings support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis... - Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85AKristin L Griffiths
The Jenner Institute, Oxford University, Oxford, United Kingdom
PLoS ONE 6:e23463. 2011..These results suggest a relationship between extracellular ATP and effector responses and unveil a possible pathway that could be targeted during vaccine design... - Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1Helen A Fletcher
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
Vaccine 26:5269-75. 2008..This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines... - Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individualsClare R Sander
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
Am J Respir Crit Care Med 179:724-33. 2009..An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care... - A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-GuerinAngela M Minassian
The Jenner Institute, University of Oxford, UK
J Infect Dis 205:1035-42. 2012..In vivo antimycobacterial immunity could be assessed using intradermal Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccination as a surrogate for M. tuberculosis infection... - Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85ASimone C de Cassan
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
Clin Vaccine Immunol 17:1066-73. 2010..These data highlight the intricate balance of effector and regulatory immune responses induced by vaccination and that preexisting immunity to mycobacterial antigens may affect the composition of vaccine-induced T-cell subsets... - Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAARTRebecca Sutherland
MRC Human Immunology Unit, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ, UK
AIDS 20:821-9. 2006..The early initiation of HAART might preserve functional CD4 T-cell responses to MTB, and warrants evaluation in populations with a high risk of dual infection... - Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteersInese Cebere
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
Vaccine 24:417-25. 2006..HIVA DNA and MVA.HIVA vaccines either alone or in a prime-boost regime to healthy HIV-1/2-negative adults indicated that the vaccines were safe and warranted further testing of this approach in larger phase I/II studies... - Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responsesAnna M Checkley
The Jenner Institute, Nuffield Department of Medicine, Oxford University, ORCRB, Oxford, United Kingdom
PLoS ONE 6:e26434. 2011..These early findings may provide a basis for characterising exposure to NTM at a population level, which has applications in the field of TB vaccine design as well as in the development of diagnostic tests... - Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacyAngela M Minassian
The Jenner Institute, University of Oxford, Oxford, United Kingdom
PLoS ONE 6:e19840. 2011..tb challenge. Translation of these findings to a human BCG challenge model could enable more rapid assessment and down selection of candidate TB vaccines and ultimately the identification of an immune correlate of protection... - Dual neonate vaccine platform against HIV-1 and M. tuberculosisRichard Hopkins
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
PLoS ONE 6:e20067. 2011..tuberculosis infant vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable and may provide a basis for lifetime protection maintained by boosts later in life... - A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian
The Jenner Institute, Oxford University, Oxford, UK
BMJ Open 1:e000223. 2011..Conclusion MVA85A is safe and immunogenic in healthy adults infected with HIV. Further safety and efficacy evaluation of this candidate vaccine in TB- and HIV-endemic areas is merited... - CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophagesRoger H Brookes
Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, GB
Eur J Immunol 33:3293-302. 2003..These data identify a previously unrecognized CD8(+) T cell-mediated mechanism used to control an intracellular infection of macrophages... - Tuberculosis vaccines in clinical trialsRosalind Rowland
The Jenner Institute, Old Road Campus Research Building, Oxford University, Oxford, OX3 7DQ, UK
Expert Rev Vaccines 10:645-58. 2011..There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen... - Tuberculosis vaccines: present and futureAngela M Minassian
Clinical Research Fellow, The Jenner Institute, University of Oxford, Old Road Campus Research Building, Level 2, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
Expert Rev Respir Med 2:721-38. 2008.... - Efficacy of follow-up and contact tracing of women who test positive for genital tract chlamydia trachomatis prior to pregnancy terminationP T Ayuk
Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington, Oxford, UK
J Obstet Gynaecol 24:687-9. 2004..003). In conclusion, follow-up and contact-tracing of women who screen positive for genital tract C. trachomatis was incomplete. This may substantially compromise the cost-effectiveness of a screen-and-treat programme... - Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosisC Sander
University of Oxford, CCVTM, Churchill Hospital, Oxford, UK
Clin Exp Immunol 147:401-11. 2007..Here, the steps involved in the development and evaluation of TB vaccines will be discussed, including description of the most frequently used animal models and the processes involved in advancing vaccines to phase III trials... - Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cellsA Lalvani
Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
Am J Respir Crit Care Med 163:824-8. 2001..tuberculosis infection and BCG vaccination. This capability may facilitate tuberculosis control in nonendemic regions... - Tuberculosis vaccines: progress and challengesAnna M Checkley
Jenner Institute, Nuffield Department of Medicine, Oxford University, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK
Trends Pharmacol Sci 32:601-6. 2011..Following this, large efficacy trials are undertaken, which face the daunting challenges of cost, logistics and trial site capacity... - Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatmentA A Pathan
Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
J Immunol 167:5217-25. 2001..tuberculosis in vivo. Such findings may assist in the design and evaluation of novel tuberculosis vaccine candidates... - Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigsA Williams
Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom
Infect Immun 73:3814-6. 2005.... - Susceptibility to tuberculosis--the importance of the pathogen as well as the hostH McShane
Nuffield Department of Medicine, University of Oxford, Centre for Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
Clin Exp Immunol 133:20-1. 2003 - Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study designHannah B Ibanga
MRC Laboratories, Fajara, The Gambia
Lancet Infect Dis 6:522-8. 2006..These issues are highly relevant to early clinical trials with all new tuberculosis vaccines in the developing world... - Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosisAnn Williams
Health Protection Agency, Porton Down, Salisbury SP4 OJG, UK
Tuberculosis (Edinb) 85:29-38. 2005..A relatively high aerosol-challenge dose and evaluation over a protracted time post-challenge allowed superior protection over BCG to be demonstrated by BCG boosted with MVA and fowl pox vectors expressing Ag85A... - The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivoMartin O C Ota
Bacterial Diseases Programme, Medical Research Council, P O Box 273, Banjul, Gambia
Vaccine 25:8861-7. 2007..We conclude that BCG is immunogenic, but this effector response is short-lived and can be limited in higher pre-existing anti-mycobacterial immunity, suggesting a possible threshold beyond which BCG immunogenicity is inhibited... - Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South AfricaTony Hawkridge
South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
J Infect Dis 198:544-52. 2008..We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic... - A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humansMatilu Mwau
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, Oxford OX3 9DS, UK
J Gen Virol 85:911-9. 2004..These results are very encouraging and justify further vaccine development...